Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Primal Kaur"'
Autor:
Michael E. Wechsler, Gene Colice, Janet M. Griffiths, Gun Almqvist, Tor Skärby, Teresa Piechowiak, Primal Kaur, Karin Bowen, Åsa Hellqvist, May Mo, Esther Garcia Gil
Publikováno v:
Respiratory Research, Vol 21, Iss 1, Pp 1-10 (2020)
Abstract Background Many patients with severe asthma continue to experience asthma symptoms and exacerbations despite standard-of-care treatment. A substantial proportion of these patients require long-term treatment with oral corticosteroids (OCS),
Externí odkaz:
https://doaj.org/article/03dab2a3f7ba4d9b9f320bbf91dd8b36
Autor:
Andrew Menzies-Gow, Gene Colice, Janet M. Griffiths, Gun Almqvist, Sandhia Ponnarambil, Primal Kaur, Gennaro Ruberto, Karin Bowen, Åsa Hellqvist, May Mo, Esther Garcia Gil
Publikováno v:
Respiratory Research, Vol 21, Iss 1, Pp 1-12 (2020)
Abstract Background Patients with severe, uncontrolled asthma have a significant unmet need for new treatments that have broader effects on airway inflammation, and that provide greater improvements in asthma outcomes than currently approved biologic
Externí odkaz:
https://doaj.org/article/1d95b73b0f56448095c718271556d711
Autor:
Michael E. Wechsler, Elliot Israel, Primal Kaur, Janet M. Griffiths, Christopher E. Brightling, Arnaud Bourdin, Andrew Menzies-gow, Gene L. Colice, Geoffrey Chupp, Gun Almqvist, Jonathan Corren, Karin Bowen, Sandhia Ponnarambil, Åsa Hellqvist
Publikováno v:
New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2021, 384 (19), pp.1800-1809. ⟨10.1056/NEJMoa2034975⟩
New England Journal of Medicine, Massachusetts Medical Society, 2021, 384 (19), pp.1800-1809. ⟨10.1056/NEJMoa2034975⟩
International audience; BACKGROUND: Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial-cell–derived cytokine implicated in the pathogenesis of asthma. The efficacy and safety of tezepelumab in patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::226239c76f26e26af91990f6d8ee416a
https://doi.org/10.1056/nejmoa2034975
https://doi.org/10.1056/nejmoa2034975
Autor:
Michael E Wechsler, Andrew Menzies-Gow, Christopher E Brightling, Piotr Kuna, Stephanie Korn, Tobias Welte, Janet M Griffiths, Kinga Sałapa, Åsa Hellqvist, Gun Almqvist, Harbans Lal, Primal Kaur, Tor Skärby, Gene Colice, Victor H Cambursano, Marcelo J Fernandez, Fernando D Scherbovsky, Anahi Yanez, Alberto J Tolcachier, Ana M Stok, Fernando J B Verra, Karin Forster, Mathias Rolke, Andrea Ludwig-Sengpiel, Tibor Schmoller, Olaf Schmidt, Katrin Milger-Kneidinger, Martin Hoffmann, Hilke Temme, Anneliese Linnhoff, Joachim Kirschner, Barbara Rewerska, Ewa Pisarczyk-Bogacka, Sang Haak Lee, Byung Jae Lee, Heung-Woo Park, Jung-Won Park, Sook Young Lee, You Sook Cho, Kwan Ho Lee, Sevim Bavbek, Bilun Gemicioglu, Dane Ediger, Ilkay Koca Kalkan, Ismail Hanta, Arzu Yorgancioglu, Yevgeniya DytyatkovsKa, Yuriy M Mostovoy, Kyrylo Lebed, Oleh Yakovenko, David I Bernstein, Jeffrey P Tillinghast, Loretta Que, Jan Madison, Todd Rambasek, Kartik Shenoy, Charles A Thompson, Christopher M Chappel, Golda Hudes, Ehab Sorial, Shahrukh A Kureishy, Syed M Rehman, Njira Lugogo, Erika G Gonzalez, Fred C Umeh, Eric J Boren, Jason Sigmon, Hummayun Ismail, Arjun Mohan, Sandeep Bansal, Thomas D Kaelin
Publikováno v:
The Lancet. Respiratory medicine. 10(7)
Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin. SOURCE evaluated the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma.We conducted this phase 3,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c4dd948337d955804717d0396d738bd
https://pubmed.ncbi.nlm.nih.gov/35395206
https://pubmed.ncbi.nlm.nih.gov/35395206
Autor:
Teresa Piechowiak, Primal Kaur, Esther Garcia Gil, Gun Almqvist, Tor Skärby, Janet M. Griffiths, Karin Bowen, May Mo, Michael E. Wechsler, Gene L. Colice, Åsa Hellqvist
Publikováno v:
Respiratory Research
Respiratory Research, Vol 21, Iss 1, Pp 1-10 (2020)
Respiratory Research, Vol 21, Iss 1, Pp 1-10 (2020)
Background Many patients with severe asthma continue to experience asthma symptoms and exacerbations despite standard-of-care treatment. A substantial proportion of these patients require long-term treatment with oral corticosteroids (OCS), often at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11a03f171e79c7d576b845ffbc819916
https://doi.org/10.1186/s12931-020-01503-z
https://doi.org/10.1186/s12931-020-01503-z
Autor:
Sandhia Ponnarambil, Gennaro Ruberto, Primal Kaur, Gun Almqvist, May Mo, Gene L. Colice, Andrew Menzies-Gow, Karin Bowen, Esther Garcia Gil, Åsa Hellqvist, Janet M. Griffiths
Publikováno v:
Respiratory Research
Respiratory Research, Vol 21, Iss 1, Pp 1-12 (2020)
Respiratory Research, Vol 21, Iss 1, Pp 1-12 (2020)
Background Patients with severe, uncontrolled asthma have a significant unmet need for new treatments that have broader effects on airway inflammation, and that provide greater improvements in asthma outcomes than currently approved biologics and sta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfb7f56ef3d7ad10383a3d4163b7eb85
https://doi.org/10.1186/s12931-020-01526-6
https://doi.org/10.1186/s12931-020-01526-6
Publikováno v:
Poster presentations.
Background/Purpose Current SLE treatment options have limited efficacy and potential toxicities that impede an individual’s ability to remain on therapy. AMG 570 is a bispecific antibody inhibiting both ICOSL and BAFF that engages ICOSL on antigen-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f537eef141354492839f943657bb4083
https://doi.org/10.1136/lupus-2020-eurolupus.176
https://doi.org/10.1136/lupus-2020-eurolupus.176
Publikováno v:
Biodrugs
Biosimilars are highly similar versions of approved branded biologics. Unlike generics, they are not exact replicas of reference products. Minor differences between biosimilars and reference products in some aspects are expected; likewise, biosimilar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf985a9b5b21dc44a6a24608a22065d3
https://doi.org/10.1007/s40259-017-0218-5
https://doi.org/10.1007/s40259-017-0218-5
Autor:
Karin Bowen, Sandhia Ponnarambil, Jonathan Corren, Gene L. Colice, Andrew Menzies-Gow, Gun Almqvist, Geoffrey Chupp, Janet M. Griffiths, Arnaud Bourdin, Primal Kaur, Åsa Hellqvist, Elliot Israel
Publikováno v:
Journal of Allergy and Clinical Immunology. 147:AB249
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75f293063d8149e14fb46df3deec4d8c
https://doi.org/10.1016/j.jaci.2020.12.050
https://doi.org/10.1016/j.jaci.2020.12.050
Autor:
Nataliya Agafonova, Reshma Kewalramani, Michael G. Dodds, Martha L. Cruz, Wendy Snyder, Sunder Mudaliar, Andrea Pellacani, Primal Kaur, Philip Raskin, Nick Manamley, Leonid Katz, Justo Sierra‐Johnson
Publikováno v:
Diabetes, Obesity and Metabolism. 18:191-195
Phase I studies have shown that AMG 151 activates glucokinase, a key enzyme in glucose homeostasis. The present randomized, placebo-controlled phase IIa study evaluated the dose-effect relationship of the glucokinase activator AMG 151 relative to pla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d02e887b4a1030d5d327669ccb72737
https://doi.org/10.1111/dom.12586
https://doi.org/10.1111/dom.12586